BiotechTube

Epetraborole + Placebo

Phase 2/3Terminated
1 views this week 0 watching💤 Quiet
Interest: 20/100
20
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

MAC Lung Disease

Conditions

MAC Lung Disease, Treatment Refractory MAC Lung Disease

Trial Timeline

May 20, 2022 → Dec 18, 2024

NCT ID
NCT05327803

About Epetraborole + Placebo

Epetraborole + Placebo is a phase 2/3 stage product being developed by AN2 Therapeutics for MAC Lung Disease. The current trial status is terminated. This product is registered under clinical trial identifier NCT05327803. Target conditions include MAC Lung Disease, Treatment Refractory MAC Lung Disease.

What happened to similar drugs?

20 of 20 similar drugs in MAC Lung Disease were approved

Approved (20) Terminated (3) Active (0)
✅Sivelestat sodium hydrate + Sivelestat sodium hydrateOno PharmaceuticalApproved
✅Pemetrexed + CarboplatinEli LillyApproved
✅pemetrexedEli LillyApproved
✅Budesonide + SymbicortAstraZenecaApproved
✅Symbicort® total dose 400ug/12ug + Symbicort® total dose 800ug/24ug + Formoterol 24ug + BUD total dose 800ugAstraZenecaApproved
✅Osimertinib+cisplatin or carboplatin + pemetrexed EditAstraZenecaApproved
✅DurvalumabAstraZenecaApproved

Hype Score Breakdown

Clinical
15
Activity
0
Company
5
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT05327803Phase 2/3Terminated
NCT04892641Phase 1Completed

Competing Products

20 competing products in MAC Lung Disease

See all competitors
ProductCompanyStageHype Score
BBP-398 with nivolumabBridgeBio PharmaPhase 1
18
Pemetrexed + CarboplatinEli LillyPhase 3
40
Necitumumab + Gemcitabine + CarboplatinEli LillyPhase 2
27
SelpercatinibEli LillyPre-clinical
26
Pemetrexed + Cisplatin + Placebo + PemetrexedEli LillyPhase 3
40
NBTXR3NanobiotixPhase 1/2
33
PemetrexedEli LillyPre-clinical
26
pemetrexed + erlotinibEli LillyPhase 2
35
Necitumumab-Gemcitabine-CisplatinEli LillyPhase 2
27
LY3295668 ErbumineEli LillyPhase 1
29
FYB206 + FYB206 + KeytrudaFormycon AGPhase 3
22
6-Thio-2'-Deoxyguanosine + CemiplimabMAIA BiotechnologyPhase 2
32
6-Thio-2'-Deoxyguanosine + Cemiplimab + Docetaxel + Vinorelbine + Gemcitabine aloneMAIA BiotechnologyPhase 3
37
pemetrexed + cisplatinEli LillyPhase 2
27
gemcitabine + carboplatin + cisplatinEli LillyPhase 2
35
CetuximabEli LillyPhase 1
29
pemetrexed + docetaxelEli LillyPhase 3
40
enzastaurin + pemetrexed + docetaxel + carboplatinEli LillyPhase 2
35
PemCarbo + Pem onlyEli LillyPhase 3
36
TNG456 + abemaciclibEli LillyPhase 1/2
39